Shorter radiation course may reduce side effects for lung cancer patients
NCT ID NCT03706027
First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time
Summary
This study compares two different schedules of stereotactic body radiotherapy (SBRT) for people with early-stage non-small-cell lung cancer. Patients are randomly assigned to receive radiation over 3 days or 5 days. The main goal is to see if one schedule causes fewer severe side effects than the other. Participants are followed by their radiation oncologist after treatment.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- stereotactic body radiotherapy (SBRT) given in either 3 fractions (54 Gy) or 5 fractions (60 Gy)
- What this could lead to
- If successful, this could show that a shorter 3-day radiation course causes fewer severe side effects than a 5-day course, potentially becoming the preferred treatment schedule.
- What could go wrong
- This is a phase II trial with only 100 participants, so results may not apply to all patients. The study focuses on side effects, not cure rates, and longer follow-up is needed to confirm safety and effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
James P. Wilmot Cancer Center at University of Rochester Medical Center
RECRUITINGRochester, New York, 14642, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Chest-Injected drug drain Cancer's fluid trap?
- Can a radioactive tracer reveal whether immunotherapy is working?
- Can a new nucleotide analogue boost cancer treatment?
- Can a pill that blocks multiple cancer proteins shrink Hard-to-Treat tumors?
- Can a Two-Pronged attack shrink Hard-to-Treat cancers?
- Breathing tube-free lung surgery tested for patients with fragile lungs